5 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | ISPOR 2025: Real-World Drivers of GLP-1 RA Discontinuation (Truveta Research) | Truveta Research | https://www.truveta.com/blog/research/ispor-2025-real-world-temporal-and-indication-specific-variation-in-drivers-of-glp-1-ra-discontinuation/ | 2025-01-01 | health | conference-presentation | unprocessed | medium |
|
Content
Truveta Research presentation at ISPOR 2025 on real-world temporal and indication-specific variation in GLP-1 RA discontinuation drivers.
Key findings on discontinuation drivers:
- Income: Patients with income >$80,000 are less likely to discontinue — financial access remains a determinant of adherence, even among commercially insured patients
- History of GI medication: 9% more likely to discontinue (side effect vulnerability)
- History of psychiatric medication: 12% more likely to discontinue (mental health comorbidity as adherence barrier)
- Cardiovascular disease or other chronic conditions: 10% more likely to discontinue
- Age 18-34: More likely to drop out early (lower chronic disease motivation, higher side effect intolerance)
- Provider specialty: Endocrinologists and obesity specialists → better 12-week completion than primary care
Temporal patterns:
- The first 4 weeks (titration phase) are the highest-risk period for dropout
- After initial titration, persistence improves but remains below 50% for non-T2D patients
- Indication matters: T2D indication → higher persistence than obesity-only (46.5% vs. 64.8% annual discontinuation)
Structural interpretation:
- Discontinuation is not random — it is systematically predicted by income, comorbidity profile, and provider type
- This means payer/coverage decisions (which stratify by income and plan type) interact with clinical discontinuation patterns to produce health equity outcomes
Agent Notes
Why this matters: The systematic predictors of discontinuation are more important than the rate alone. Income predicting persistence means that affordable access (compounding, Medicaid coverage, employer coverage) would differentially IMPROVE adherence among the highest-need patients — who are currently both less likely to access AND more likely to discontinue when they do access.
What surprised me: The psychiatric medication history correlation. 12% MORE likely to discontinue means that the patients with co-occurring mental health conditions — who have the highest obesity burden AND the highest metabolic disease risk — are also the patients who can't stay on GLP-1 therapy. This is a compounding access-adherence trap: highest need → lowest access → lowest persistence.
What I expected but didn't find: Data on whether the income and provider type effects persist after controlling for drug cost (i.e., is income predicting adherence because of cost, or because of behavioral factors independent of cost?). The mechanism matters for intervention design.
KB connections:
- Enriches the access equity claims (KFF series: race, income disparities in GLP-1 access)
- The psychiatric comorbidity finding connects to behavioral health claims — co-occurring mental health and metabolic disease is an undertreated cluster
- Provider specialty effect (endocrinologists better) connects to the specialist vs. generalist care quality literature
- Cross-domain: the income/adherence interaction is a social determinants story — income predicts BOTH access AND adherence outcomes
Extraction hints:
- The psychiatric comorbidity + discontinuation interaction is extractable: "GLP-1 adherence is lowest among the patients with highest comorbidity burden — creating an access-adherence trap where the most metabolically vulnerable patients are both least likely to access GLP-1s and most likely to discontinue when they do"
- The provider specialty effect is independently extractable: obesity specialists achieve better adherence — supporting specialized obesity medicine infrastructure investment
- Income >$80K persistence advantage should be combined with KFF equity archives to make the full equity argument
Context: Truveta is a health data analytics company using real-world EHR data. ISPOR is the leading health economics/outcomes research conference. Conference presentation data is pre-publication — findings subject to revision — but represents real-world patterns.
Curator Notes (structured handoff for extractor)
PRIMARY CONNECTION: GLP-1 access equity (KFF archives) + adherence mechanism WHY ARCHIVED: The systematic discontinuation predictors (income, psychiatric comorbidity, provider type) are more actionable than aggregate discontinuation rates. These are the intervention targets. EXTRACTION HINT: Use with KFF equity archives to make a combined claim about the access-adherence trap for highest-need populations. The psychiatric comorbidity finding is the most novel and underappreciated.